Disc Medicine Q1 net loss $34.1M, cash $694.7M; bitopertin NDA on track H2 2025

Disc Medicine, Inc.

2025-Q1 EPS reported -$1.02

Ended Q1 with $694.7M cash; expects to fund operations into 2028 after $259M January offering.
Net loss $34.1M vs $26.9M YoY; R&D expense $27.8M, SG&A $12.2M, both up on pipeline progress.
Bitopertin NDA in erythropoietic protoporphyria (EPP) planned for H2 2025; APOLLO confirmatory trial initiated.
DISC-3405 Phase 2 in polycythemia vera expected to start H1 2025; initial DISC-0974 data due H2 2025.
Successful CMC-focused end-of-Phase-2 meeting with FDA; drug substance and product manufactured in US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.